11 results about "Ocular tension" patented technology

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

A plug for aqueous humor drainage tubes, an implantation device, and a removal device include a plug body, which is a conical structure. The bottom surface of the conical plug body is provided with a connecting protrusion extending outward, and the bottom surface of the plug body is provided with a magnetic connection structure. The magnetic connection structure is fixedly connected to the bottom surface of the plug body. The bottom surface of the plug body is also provided with an expansion layer structure, which is connected to the bottom surface of the plug body and covers the magnetic connection structure. The end of the magnetic connection structure extends outside the expansion layer structure. The present invention temporarily blocks the aqueous humor drainage tube of a glaucoma drainage implant to reduce the deposition of lens fragments, viscoelastics, inflammatory substances, etc. in the drainage tube during surgery, thereby reducing the intraocular pressure fluctuation of glaucoma patients after cataract surgery and avoiding the failure of glaucoma drainage implant surgery.

The invention provides a gRNA, an AAV expression vector and a CRISPR-CasRx system for treating glaucoma, and particularly provides (a) a gene editing protein or an expression vector thereof, the gene editing protein comprises a VI type Cas protein; and (b) gRNA or an expression vector thereof, the gRNA is RNA for guiding the gene editing protein to be specifically combined with an aqueous humor outflow related gene and / or an aqueous humor generation related gene in an eye tissue, the aqueous humor outflow related gene comprises Rock1 and Rock2, and the aqueous humor generation related gene comprises Aqp1 and Adrb2. The gRNA designed aiming at exon regions of aqueous fluid outflow related genes (such as Rock1 and Rock2) and aqueous fluid generation related genes (such as Aqp1 and Adrb2) has the characteristics of relatively high editing efficiency and relatively low off-target rate, and the combination of the VI type Cas protein and the gRNA designed by the invention can effectively prevent and / or treat glaucoma or ocular hypertension.

Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w / v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

The invention discloses a calycosin-7-glucoside PLGA hydrogel applied to glaucoma surgery, and relates to the technical field of biological medicine, and the calycosin-7-glucoside PLGA hydrogel is prepared from the following components by weight: 1-5 parts of calycosin-7-glucoside, 20-40 parts of PLGA, 0.1-3 parts of an emulsion stabilizer, 3-8 parts of a hydrogel matrix, and 3-8 parts of a cross-linking agent. Through the construction of a dual slow-release system, the sustained release time is long, and the peak period of scar hyperplasia after operation can be covered; the semi-solid gel is attached to the sclera flap in a form, so that the adhesiveness of the surgical site is improved, and the side effects of the whole body and the secondary surgical rate can be reduced; the biocompatibility is excellent, no obvious toxicity or stimulation exists, and complications (such as low intraocular pressure and inflammation) of traditional anti-metabolic drugs can be avoided.

Provided herein are solid forms, e.g., polymorphs, of 2-(3-((7R, 8aS)-7-fluorohexahydropyrrolo [1, 2-a] pyrazine-2 (1H)-yl)-1-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl) amino) pyrimidin-4-yl) azetidin-3-yl) acetonitrile, which are useful in the treatment of kinase-related diseases or disorders. The solid forms and compositions thereof are useful for treating diseases in a subject, including but not limited to ocular diseases such as glaucoma, ocular hypertension, ocular wound repair, neurodegenerative ocular diseases, retinal detachment, and non-ocular diseases such as neuronal injury or skin wound repair, or inflammatory diseases, etc. (Compound 1). # imgabs0 #

The invention provides a glaucoma drainage implant suitable for internal and external implantation, the glaucoma drainage implant is used for drainage of aqueous humor of an anterior chamber to reduce intraocular pressure, a schlemm tube can be implanted through an internal approach or an external approach, the glaucoma drainage implant is linear or arc-shaped in a non-implantation state, and the glaucoma drainage implant can adapt to the curvature of the schlemm tube after implantation, the glaucoma drainage implant comprises two tubular bodies and a connecting body, the connecting body is connected with the two tubular bodies, the two tubular bodies are located at the two opposite ends of the glaucoma drainage implant in the axial direction of the glaucoma drainage implant respectively, barb structures are arranged on the outer surfaces of the tubular bodies, the tubular bodies are provided with hollow inner cavities, first open grooves are further formed in the outer surfaces of the tubular bodies in the axial direction of the tubular bodies, and the first open grooves are communicated with the first open grooves. And aqueous humor can flow through the hollow inner cavity, the barb structure and the first open groove. The glaucoma drainage implant can be implanted into the schlemm tube at a time through the inner approach or the outer approach, the implantation efficiency is high, and the operation difficulty is low. The invention further provides a drainage device for guiding the glaucoma drainage implant to be implanted into the schlemm tube.

Provided are a two-component combination pharmaceutical composition and use thereof, which belong to the field of pharmaceuticals. The pharmaceutical composition comprises: carteolol or timolol, netarsudil, a buffer, a tonicity agent, a pH regulator, a tackifier, and water for injection. By adding the pH regulator to a solution of netarsudil free base and carteolol free base or timolol free base, the problem that netarsudil is immiscible with carteolol or timolol is successfully solved. The preparation process is simple, the intraocular pressure is reduced by means of different mechanisms of action, and the therapeutic effect is significant and precise. The ophthalmic pharmaceutical composition provides the possibility for clinically safe and effective reduction of intraocular pressure and treatment of glaucoma.

The invention relates to the technical field of glaucoma treatment equipment, in particular to a sustained-release administration glaucoma drainage stent and a preparation method thereof.The sustained-release administration glaucoma drainage stent comprises a stent body, the stent body comprises a drainage tube and a disc, the surface of the stent body is coated with an anti-scar drug coating, and the anti-scar drug coating is prepared by mixing an anti-scar drug and a degradable polymer; a plurality of micro-cavities and drainage channels are arranged on the disc, the drainage channels penetrate through the micro-cavities and are communicated with the interiors of the micro-cavities, one end of the drainage tube extends into the disc and is communicated with the drainage channels, intraocular pressure reducing slow-release compounds are arranged in the micro-cavities, and porous membranes are arranged at the ends, communicated with the drainage channels, of the micro-cavities. Through the dual structure of the surface anti-scar drug coating and the built-in intraocular pressure reduction drug storage, the anti-scar and intraocular pressure reduction synergistic treatment is achieved, the glaucoma treatment effect and safety are improved, and remarkable breakthrough is achieved in the aspects of clinical treatment effect, safety, patient compliance and the like.

The present invention discloses an ocular implant, comprising an implant body, wherein the implant body is in the shape of a strip, and the outer contour of the upper surface thereof is in the shape of a convex arch or semi-arch, for contacting the sclera, and the lower surface of the implant body is in the shape of a plane, for contacting the choroid; a longitudinal drainage groove is provided on the upper surface of the implant body along the front-to-back direction of the implant body. The implant body as a whole is in the structure of being gradually thinner at the front and back ends and thicker in the middle, or gradually thinner at the back end and thicker in the middle to the front end, so that it can smoothly enter the suprachoroidal space, expand the originally narrow suprachoroidal space, and increase the outflow of aqueous humor from the suprachoroidal space by means of the longitudinal drainage groove, thus having a good drainage effect, not prone to clogging, and playing a role in reducing intraocular pressure. The lower surface of the implant body is in the shape of a plane, and the area of ​​contact with the choroid is larger, which is conducive to stable attachment to the choroid, reducing the risk of displacement to the anterior chamber and choroid, avoiding exposure to the anterior chamber and touching the cornea, and minimizing the risk of corneal endothelial cell loss.